An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that Dr. Todd C. Brady will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference. The conversation will be available on demand starting at 7:00 a.m. ET on January 10, 2022. Aldeyra specializes in therapies for immune-mediated diseases, with products like reproxalap and ADX-629 in various clinical trial phases. Reproxalap is in Phase 3 trials for dry eye disease and allergic conjunctivitis, while ADX-629 is in Phase 2 trials for psoriasis and COVID-19. The webcast can be accessed on their website.
Positive
None.
Negative
None.
Webcast Available On Demand Beginning at 7:00 a.m. ET Monday, January 10
LEXINGTON, Mass.--(BUSINESS WIRE)--
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference.
Dr. Brady’s conversation with Edwin Zhang, Ph.D., MBA, Managing Director and Senior Healthcare Analyst for H.C. Wainwright, will be available on demand beginning at 7:00 a.m. ET Monday, January 10, 2022. To view the webcast, log in to the Investors & Media section of the Aldeyra Therapeutics website at https://ir.aldeyra.com. The event will remain archived on the website for 90 days.
About Aldeyra Therapeutics
Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies designed to modulate immunological systems, without inhibiting or activating single targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, atopic asthma, and COVID-19. Our clinical pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in Phase 3 clinical testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.
Corporate:
Joshua Reed Aldeyra Therapeutics, Inc. 781-761-4904 ext. 218
jreed@aldeyra.com
Investors & Media:
Scott Solomon Sharon Merrill Associates, Inc. 617-542-5300
ALDX@investorrelations.com
Source: Aldeyra Therapeutics, Inc.
FAQ
What is the date and time for the Aldeyra Therapeutics fireside chat?
The fireside chat will be available on demand starting at 7:00 a.m. ET on January 10, 2022.
Who is participating in the Aldeyra Therapeutics fireside chat?
Dr. Todd C. Brady, President and CEO of Aldeyra Therapeutics, will participate in the chat.
Where can I watch the Aldeyra Therapeutics fireside chat?
The fireside chat can be viewed on Aldeyra Therapeutics' website under the Investors & Media section.
What are the lead product candidates being developed by Aldeyra Therapeutics?
Aldeyra's lead product candidates include reproxalap and ADX-629, targeting immune-mediated diseases.
What clinical trials are ongoing for Aldeyra's products?
Reproxalap is in Phase 3 trials for dry eye disease and allergic conjunctivitis, while ADX-629 is in Phase 2 trials for psoriasis, atopic asthma, and COVID-19.
